InvestorsHub Logo
Followers 840
Posts 120472
Boards Moderated 18
Alias Born 09/05/2002

Re: None

Monday, 11/08/2021 9:41:32 AM

Monday, November 08, 2021 9:41:32 AM

Post# of 1168
BMY reports statsig DFS in neoadjuvant* NSCLC:

https://finance.yahoo.com/news/neoadjuvant-opdivo-nivolumab-plus-chemotherapy-115900324.html

These data are from the phase-3 CHECKMATE-816 study. BMY reported stellar pCR (complete pathological response) data from this trial in Apr 2021 (#msg- 163102660), but the DFS (primary endpoint) data were not yet mature then.

This result should enable Opdivo to compete with Tecentriq use in adjuvant NSCLC.

See #msg-163102660 for background info.

*Stage Ib to IIIa.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News